Jefferies raises Centene stock price target to $69 on earnings power
Jefferies raised its price target on Centene (CNC) to $69, citing strong earnings power and navigation of headwinds. The stock trades at $67.05, below a Fair Value of $77.79. Jefferies estimates 2027 EPS of $6.07, with Medicaid medical loss ratio as a key variable. Centene reported Q3 2026 earnings of $0.58 per share, exceeding estimates, and raised its full-year EPS outlook. Cantor Fitzgerald and BofA Securities also increased their price targets.
How this was made
The 30-second read
Why it matters
The upgrades reflect confidence in Centene's earnings power and margin recovery, potentially driving short‑term buying interest.
Market read
Analyst upgrades on strong earnings could lift Centene and related health insurer stocks.
What to watch
Potential regulatory scrutiny on Medicaid loss ratios could cap upside.
Background
Analyst firms updated their price targets for Centene after the company's Q3 2026 earnings beat expectations.
Ticker impact
Jefferies and Cantor Fitzgerald raised Centene's price target to $69 and $79 respectively, citing strong Q3 earnings and outlook.
likely upward pressure as investors price in higher valuation multiples.
Multiple analysts increased targets on the same day, reflecting fresh optimism on earnings and margin recovery.
Market effects
Positive signal for the health insurer sector and Medicaid-dependent stocks.
U.S. healthcare equities may see modest gains.
Limited to U.S. markets.
Counterpoint
Target raises may be premature if Medicaid cost pressures re‑emerge.
Key entities
- companyCentene Corp.
U.S. health insurer (ticker CNC).
- analyst_firmJefferies
Raised target to $69, Hold rating.
- analyst_firmCantor Fitzgerald
Raised target to $79, Overweight rating.
